Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 12;9(2):e002100. doi: 10.1136/jitc-2020-002100

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Rate of response (left) and the best overall response (right) in model-predicted tumor diameter of 100 randomly selected virtual patients. Response is assessed by RECIST V.1.131 in atezolizumab monotherapy (A), nab-paclitaxel group (B), and atezolizumab+nab-paclitaxel group (C). Median (thick lines) and individual (thin line) rate of response are shown in PD (red), SD (purple), and PR/CR (blue) subgroups. CR, complete response; nab, nanoparticle albumin-bound; PD, progressive disease; PR, partial response; SD, stable disease.